Search results for Anti-LRRK2 Antibody

Anti-LRRK2 Antibody, Alomone Labs, ANR-102

Anti-LRRK2 Antibody(#ANR-102) is a highly specific antibody directed against an epitope of the mouse protein. The antibody can be used in western blot and immunohistochemistry applications. It has been designed to recognize LRKK2 from human, mouse, and rat samples. Anti-LRRK2 Antibody –(Carrier Free) (#ANR-102-CF) is a highly specific antibody directed against an epitope of the mouse protein. This ready-to-use, carrier-free formulation is free of BSA and sodium azide, making it ideal for conjugation, sensitive downstream applications and specialized assay development. The size of this version is0.2 mlat a concentration of1 mg/ml. It has been designed to recognize LRKK2 from human, mouse, and rat samples. Carrier Free: Anti-LRRK2 Antibody –(Carrier Free) (#ANR-102-CF) is a highly specific antibody directed against an epitope of the mouse protein. This ready-to-use, carrier-free formulation is free of BSA and sodium azide, making it ideal for conjugation, sensitive downstream applications and specialized assay development. The size of this version is0.2 mlat a concentration of1 mg/ml. It has been designed to recognize LRKK2 from human, mouse, and rat samples.

Anti-LRRK2 Antibody, Alomone Labs, ANR-102-CF

Anti-LRRK2 Antibody(#ANR-102) is a highly specific antibody directed against an epitope of the mouse protein. The antibody can be used in western blot and immunohistochemistry applications. It has been designed to recognize LRKK2 from human, mouse, and rat samples. Anti-LRRK2 Antibody –(Carrier Free) (#ANR-102-CF) is a highly specific antibody directed against an epitope of the mouse protein. This ready-to-use, carrier-free formulation is free of BSA and sodium azide, making it ideal for conjugation, sensitive downstream applications and specialized assay development. The size of this version is0.2 mlat a concentration of1 mg/ml. It has been designed to recognize LRKK2 from human, mouse, and rat samples. Carrier Free: Anti-LRRK2 Antibody –(Carrier Free) (#ANR-102-CF) is a highly specific antibody directed against an epitope of the mouse protein. This ready-to-use, carrier-free formulation is free of BSA and sodium azide, making it ideal for conjugation, sensitive downstream applications and specialized assay development. The size of this version is0.2 mlat a concentration of1 mg/ml. It has been designed to recognize LRKK2 from human, mouse, and rat samples.

Anti-LRRK2 Antibody (R3U92), AntibodySystem, RHJ02206

Anti-LRRK2 Antibody (R3U93), AntibodySystem, RHJ02207

Anti-LRRK2 antibody [MJFF2 (c41-2)], Abcam, AB133474

Product Specifications Anti-LRRK2 antibody [MJFF2 (c41-2)] (ab133474) was developed by Abcam using patented rabbit monoclonal antibody technology and is validated for use in IP, WB in human, mouse samples. Anti-LRRK2 antibody [MJFF2 (c41-2)] (ab133474) specifically detects LRRK2 (UniProt ID: Q5S007; Molecular weight: 286kDa) and is sold in 100 µL and 1 mL selling sizes. Anti-LRRK2 antibody [MJFF2 (c41-2)] (ab133474) was developed by Abcam in partnership with the Michael J. Fox Foundation for Parkinson's Research. Quality and Validation Abcam's high quality manufacturing and validation processes ensure Anti-LRRK2 antibody [MJFF2 (c41-2)] (ab133474) has high sensitivity and specificity alongside high lot-to-lot consistency and reproducibility. The specificity of Anti-LRRK2 antibody [MJFF2 (c41-2)] (ab133474) has been confirmed by testing in knockout samples. Anti-LRRK2 antibody [MJFF2 (c41-2)] (ab133474) has been cited over 120 times in peer reviewed journals and is trusted by the scientific community. Related Products Conjugation-ready, carrier free format available for antibody clone MJFF2 (c41-2) - ab172378 . Antibody clone MJFF2 (c41-2) is also available pre-conjugated to a variety of labels for your convenience - HRP ( ab195024 ). Well-characterized antibodies to efficiently detect and purify LRRK2 protein are a critical need in the Parkinson's Disease (PD) research community. To help accelerate LRRK2 research, The Michael J. Fox Foundation (MJFF), working with Abcam, has generated unique and high quality LRRK2 rabbit monoclonal antibodies to be widely available for PD research community. LRRK2 (Leucine-rich repeat kinase 2, dardarin) is a protein kinase belonging to the ROCO family, which is defined by the presence of a ROC (Ras/GTPase of complex proteins) domain and COR (C-terminal of Roc) region. LRRK2 exhibits kinase activity whereby it can undergo autophosphorylation and can phosphorylate generic substrates. In addition, the GTPase domain of LRRK2 can mediate GDP (guanosine-5'-diphosphate)/GTP (guanosine-5'-triphosphate) binding as well as GTP hydrolysis. LRRK2 is mutated in a significant number of Parkinson's disease (PD) patients. Mutations in this gene account for 4% of PD, and are observed in 1% of sporadic PD patients. Clinical symptoms of patients carrying PD-associated mutations of LRRK2 are indistinguishable from typical sporadic PD. The spectra of neuropathological features of PARK8 (type 8), the type corresponding to LRRK2, is broad and appears to encompass those associated with other familial PD cases such as PARK1 (alpha-synuclein) and PARK2 (Parkin). Patients with this gene mutation have typical relatively late onset Parkinsonism with features comparable with idiopathic PD; symptoms include asymmetric rest tremor, bradykinesia, rigidity, and a good response to 3,4-dihyroxy-l-phenylalanine (l-DOPA). The pathology of cases with LRRK2 mutations is pleomorphic. For more characterization data and protocols using this LRRK2 Antibody, please refer to Davies, et al. 2013. Biochemical J 453(1):101-113 [PMID: 23560750] Abcam recommended secondaries - Goat Anti-Rabbit HRP ( ab205718 ) and Goat Anti-Rabbit Alexa Fluor® 488 ( ab150077 ). Or search our wide range of secondary antibodies for use with your experiment. Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies . Collaborations This antibody was developed with support from The Michael J. Fox Foundation.

Anti-LRRK2 antibody [MJFF3 (c69-6)], Abcam, AB133475

Well-characterized antibodies to efficiently detect and purify LRRK2 protein are a critical need in the Parkinson's Disease (PD) research community. To help accelerate LRRK2 research, The Michael J. Fox Foundation (MJFF), working with Abcam, has generated unique and high quality LRRK2 rabbit monoclonal antibodies to be widely available for PD research community. LRRK2 (Leucine-rich repeat kinase 2, dardarin) is a protein kinase belonging to the ROCO family, which is defined by the presence of a ROC (Ras/GTPase of complex proteins) domain and COR (C-terminal of Roc) region. LRRK2 exhibits kinase activity whereby it can undergo autophosphorylation and can phosphorylate generic substrates. In addition, the GTPase domain of LRRK2 can mediate GDP (guanosine-5′-diphosphate)/GTP (guanosine-5′-triphosphate) binding as well as GTP hydrolysis. LRRK2 is mutated in a significant number of Parkinson's disease (PD) patients. Mutations in this gene account for 4% of PD, and are observed in 1% of sporadic PD patients. Clinical symptoms of patients carrying PD-associated mutations of LRRK2 are indistinguishable from typical sporadic PD. The spectra of neuropathological features of PARK8 (type 8), the type corresponding to LRRK2, is broad and appears to encompass those associated with other familial PD cases such as PARK1 (alpha-synuclein) and PARK2 (Parkin). Patients with this gene mutation have typical relatively late onset Parkinsonism with features comparable with idiopathic PD; symptoms include asymmetric rest tremor, bradykinesia, rigidity, and a good response to 3,4-dihyroxy-l-phenylalanine (l-DOPA). The pathology of cases with LRRK2 mutations is pleomorphic. For more characterization data and protocols using this LRRK2 Antibody, please refer to Davies, et al. 2013. Biochemical J 453(1):101-113 [PMID: 23560750] Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies . Collaborations This antibody was developed with support from The Michael J. Fox Foundation.

Anti-LRRK2 antibody [MJFF4 (c81-8)], Abcam, AB133476

Well-characterized antibodies to efficiently detect and purify LRRK2 protein are a critical need in the Parkinson's Disease (PD) research community. To help accelerate LRRK2 research, The Michael J. Fox Foundation (MJFF), working with Abcam, has generated unique and high quality LRRK2 rabbit monoclonal antibodies to be widely available for PD research community. LRRK2 (Leucine-rich repeat kinase 2, dardarin) is a protein kinase belonging to the ROCO family, which is defined by the presence of a ROC (Ras/GTPase of complex proteins) domain and COR (C-terminal of Roc) region. LRRK2 exhibits kinase activity whereby it can undergo autophosphorylation and can phosphorylate generic substrates. In addition, the GTPase domain of LRRK2 can mediate GDP (guanosine-5′-diphosphate)/GTP (guanosine-5′-triphosphate) binding as well as GTP hydrolysis. LRRK2 is mutated in a significant number of Parkinson's disease (PD) patients. Mutations in this gene account for 4% of PD, and are observed in 1% of sporadic PD patients. Clinical symptoms of patients carrying PD-associated mutations of LRRK2 are indistinguishable from typical sporadic PD. The spectra of neuropathological features of PARK8 (type 8), the type corresponding to LRRK2, is broad and appears to encompass those associated with other familial PD cases such as PARK1 (alpha-synuclein) and PARK2 (Parkin). Patients with this gene mutation have typical relatively late onset Parkinsonism with features comparable with idiopathic PD; symptoms include asymmetric rest tremor, bradykinesia, rigidity, and a good response to 3,4-dihyroxy-l-phenylalanine (l-DOPA). The pathology of cases with LRRK2 mutations is pleomorphic. For more characterization data and protocols using this LRRK2 Antibody, please refer to Davies, et al. 2013. Biochemical J 453(1):101-113 [PMID: 23560750]. Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies . Collaborations This antibody was developed with support from The Michael J. Fox Foundation.

Anti-LRRK2 antibody [MJFF5 (68-7)], Abcam, AB181386

Well-characterized antibodies to efficiently detect and purify LRRK2 protein are a critical need in the Parkinson's Disease (PD) research community. To help accelerate LRRK2 research, The Michael J. Fox Foundation (MJFF), working with Epitomics, Inc., has generated unique and high quality LRRK2 rabbit monoclonal antibodies to be widely available for PD research community. LRRK2 (Leucine-rich repeat kinase 2, dardarin) is a protein kinase belonging to the ROCO family, which is defined by the presence of a ROC (Ras/GTPase of complex proteins) domain and COR (C-terminal of Roc) region. LRRK2 exhibits kinase activity whereby it can undergo autophosphorylation and can phosphorylate generic substrates. In addition, the GTPase domain of LRRK2 can mediate GDP (guanosine-5′-diphosphate)/GTP (guanosine-5′-triphosphate) binding as well as GTP hydrolysis. LRRK2 is mutated in a significant number of Parkinson's disease (PD) patients. Mutations in this gene account for 4% of PD, and are observed in 1% of sporadic PD patients. Clinical symptoms of patients carrying PD-associated mutations of LRRK2 are indistinguishable from typical sporadic PD. The spectra of neuropathological features of PARK8 (type 8), the type corresponding to LRRK2, is broad and appears to encompass those associated with other familial PD cases such as PARK1 (alpha-synuclein) and PARK2 (Parkin). Patients with this gene mutation have typical relatively late onset Parkinsonism with features comparable with idiopathic PD; symptoms include asymmetric rest tremor, bradykinesia, rigidity, and a good response to 3,4-dihyroxy-l-phenylalanine (l-DOPA). The pathology of cases with LRRK2 mutations is pleomorphic. This antibody clone (c68-7) has been re-introduced to the Epitomics catalog as characterization efforts have indicated that it performs very well at immunoprecipitating LRRK2 protein from cell lines and tissue lysate. This may facilitate investigators' ability to more broadly examine alterations in LRRK2 protein levels and activity to interrogate changes in the biological samples. For more characterization data and protocols using this LRRK2 Antibody, please refer to Davies, et al. 2013. Biochemical J 453(1):101-113 [PMID: 23560750] Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies . Species reactivity Rat: We have preliminary internal testing data to indicate this antibody may not react with this species. Please contact us for more information. Collaborations This antibody was developed with support from The Michael J. Fox Foundation.

Anti-LRRK2 antibody [UDD3 30(12)], Abcam, AB133518

In recent years, a critical need in the Parkinson's Disease (PD) research community has been access to well-characterized antibodies that can be used to efficiently detect and purify Leucine-Rich Repeat Kinase 2 (LRRK2) protein. The Michael J. Fox Foundation (MJFF) has supported this effort by partnering with Dr. Dario Alessi (MRC Protein Phosphorylation Unit, University of Dundee) to help accelerate LRRK2 research. Dr. Alessi has characterized unique and high quality LRRK2 rabbit monoclonal antibodies, generated by Epitomics, to be made widely available for PD research community. LRRK2 (Leucine-rich repeat kinase 2, dardarin) is a multi-domain protein belonging to the ROCO family of proteins that contains a kinase and GTPase domain among its many protein interaction domains. LRRK2 is mutated in a significant number of Parkinson's disease (PD) patients. Mutations in this gene account for 4% of PD, and are observed in 1% of sporadic PD patients. The most common mutation replaces glycine 2019 with a serine that results in increased LRRK2 kinase activity. This indicates that inhibitors of LRRK2 kinase activity might be of therapeutic benefit for the treatment of Parkinson's disease and has stimulated much activity in this field of research. The Dundee-MJFF LRRK2[100-500] total antibody will be of great utility in further understanding LRRK2 as it relates to Parkinson's disease. It should be noted this antibody is highly selective and sensitive and can readily be used to monitor LRRK2 protein levels in immunoblot analysis of 2-20 microgram amounts of whole cell extract. The LRRK2[100-500] total antibody recognizes both mouse and human endogenous LRRK2. Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies . Collaborations This antibody was developed with support from The Michael J. Fox Foundation.

Biotin Anti-LRRK2 antibody [N231B/34], Abcam, AB186324

The clone number has been updated from S231B-34 to N231B/34, both clone numbers name the same antibody clone.